HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure

PHASE4CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 22, 2017

Primary Completion Date

September 17, 2019

Study Completion Date

September 17, 2019

Conditions
Mother to Child HIV Transmission
Interventions
DRUG

Reinforced preventive ARV therapy

"If the mother is HIV-1 or HIV 1/2 infected:~* zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.~* nevirapine: 15mg/OD if weight ≥ 2500g / 10mg/OD if weight = 2000-2499g / 2mg/kg/OD if weight \< 2000g for 12 weeks in case of HIV-1 infection. After 6 weeks, nevirapine will increase at 20mg/OD~If the mother is HIV-2 infected:~\- zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks."

Trial Locations (1)

Unknown

Hôpital National Ignace Deen, Conakry

All Listed Sponsors
lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT03642704 - HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure | Biotech Hunter | Biotech Hunter